Edition:
United Kingdom

Bergenbio ASA (BGBIO.OL)

BGBIO.OL on Oslo Stock Exchange

26.90NOK
3:25pm GMT
Change (% chg)

kr-0.10 (-0.37%)
Prev Close
kr27.00
Open
kr27.00
Day's High
kr27.50
Day's Low
kr26.60
Volume
134,584
Avg. Vol
78,078
52-wk High
kr54.80
52-wk Low
kr25.00

Latest Key Developments (Source: Significant Developments)

Bergenbio Announces Start Of Phase I Trial Evaluating BGB149
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Bergenbio ASA ::BERGENBIO ANNOUNCES START OF PHASE I TRIAL EVALUATING FIRST-IN-CLASS.PHASE I STUDY WILL INVESTIGATE SAFETY AND PHARMACOKINETICS IN HEALTHY VOLUNTEERS.BERGENBIO - EXPECTS RESULTS FROM PHASE I TRIAL IN 2019, TO ANNOUNCING BGB149'S FURTHER CLINICAL DEVELOPMENT STRATEGY IN COMING MONTHS.ANNOUNCES START OF PHASE I TRIAL EVALUATING FIRST-IN-CLASS ANTI-AXL ANTIBODY BGB149.  Full Article

Bergenbio Q3 Net Loss Widens To NOK 37.7 Million
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Bergenbio ASA ::: RESULTS FOR THE THIRD QUARTER 2018.TOTAL OPERATING EXPENSES FOR Q3 WERE NOK 38.1 MILLION (NOK 36.6 MILLION).Q3 NET LOSS NOK 37.7 MILLION VERSUS LOSS NOK 35.4 MILLION YEAR AGO.  Full Article

BerGenBio Q2 Net Loss Widens To NOK 49.2 Million
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - BerGenBio ASA ::Q2 OPERATING LOSS NOK 50.7 MILLION VERSUS LOSS NOK 33.8 MILLION YEAR AGO.Q2 NET LOSS NOK 49.2 MILLION VERSUS LOSS NOK 34.1 MILLION YEAR AGO.  Full Article

Bergenbio Q1 Operating Loss Narrows To NOK 54.8 Million
Tuesday, 15 May 2018 

May 15 (Reuters) - Bergenbio ASA ::Q1 OPERATING LOSS NOK 54.8 MILLION VERSUS LOSS NOK 65.8 MILLION YEAR AGO.Q1 NET LOSS NOK 53.8 MILLION VERSUS LOSS NOK 65.1 MILLION YEAR AGO.  Full Article

BerGenBio: Promising Data Highlighting Selective AXL Inhibitor
Wednesday, 18 Apr 2018 

April 18 (Reuters) - BERGENBIO ASA ::BERGENBIO: PROMISING DATA HIGHLIGHTING SELECTIVE AXL INHIBITOR.DATA HIGHLIGHT BEMCENTINIB'S POTENTIAL TO REVERSE TUMOUR IMMUNE SUPPRESSION AND ENHANCE IMMUNE CHECKPOINT INHIBITOR EFFICACY.  Full Article

Bergenbio: Promising Pre Clinical Data Supporting Bergenbio's Pipeline To Be Published
Friday, 13 Apr 2018 

April 13 (Reuters) - BERGENBIO ASA ::PROMISING PRE-CLINICAL DATA SUPPORTING BERGENBIO'S PIPELINE TO BE PUBLISHED AND PRESENTED AT UPCOMING LEADING CONFERENCES.  Full Article

Bergenbio ‍Gets Approval From FDA
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Bergenbio Asa ::‍GAINED REQUIRED APPROVALS FROM US FDA PRIOR TO STARTING STUDY WITH BGB324​.‍IS IN DISCUSSIONS WITH REK IN BERGEN AND NORWEGIAN BOARD OF HEALTH TO GAIN APPROVAL TO CONDUCT BGBC004 STUDY IN US​.  Full Article

Bergenbio Q3 operating loss widens to NOK 36.6 mln
Friday, 17 Nov 2017 

Nov 17 (Reuters) - BERGENBIO ASA ::Q3 REVENUE NOK 36.6 MILLION VERSUS NOK 16.3 MILLION YEAR AGO.Q3 OPERATING LOSS NOK 36.6 MILLION VERSUS LOSS NOK 16.3 MILLION YEAR AGO.  Full Article

Bergenbio Q3 operating loss widens to NOK 36.6 million
Friday, 17 Nov 2017 

Nov 17 (Reuters) - BERGENBIO ASA :Q3 OPERATING EXPENSES NOK 36.6 MILLION VERSUS NOK 16.3 MILLION YEAR AGO.Q3 OPERATING LOSS NOK 36.6 MILLION VERSUS LOSS NOK 16.3 MILLION YEAR AGO.  Full Article

BerGenBio Q1 net loss widens to NOK 65.1 mln
Tuesday, 23 May 2017 

May 23 (Reuters) - BERGENBIO ASA ::Q1 NET LOSS NOK 65.1 MILLION VERSUS LOSS NOK 20.3 MILLION YEAR AGO.Q1 OPERATING LOSS NOK 65.8 MILLION VERSUS LOSS NOK 20.7 MILLION YEAR AGO.THE COMPANY IS PROGRESSING FOUR PHASE II CLINICAL TRIALS WITH BGB324 TOWARDS SIGNIFICANT VALUE INFLECTION POINTS, WITH READ-OUTS EXPECTED IN 2018.  Full Article